
    
      Approximately 12 participants will be enrolled in the study. Assessed will be safety and
      tolerability of FX-322 administered by intratympanic injection. Also assessed will be the
      FX-322 concentration in cochlear fluid (perilymph), the pharmacokinetic (PK) profile of
      FX-322 to determine the systemic exposure to FX-322.
    
  